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Summary 
 
The process of parturition whether physiological at term or pathological in preterm labour is a 
complex one driven by fetal, placental and maternal signals. There is compelling evidence to 
suggest that inflammatory mediators, driven  by endogenous factors or pathologically by 
infection, play a crucial role in stimulating the common parturition pathway leading into 
cervical ripening, uterine contractions and, finally, expulsion of the foetus and placenta. 
Toll-like receptors (TLRs) are a relatively recently discovered family of pattern recognition 
molecules which have been shown to play a pivotal role in innate immune responses and 
inflammation. Products of micro-organisms, e.g. bacteria, viruses or fungi, can be considered 
to be primary ligands of Toll-like receptors. In addition, they are also activated by other 
endogenous ligands such as heat shock protein 60 and 70, extra domain A of fibronectin and 
surfactant protein A (SPA). Therefore, local activation of Toll-like receptors may be 
responsible for initiation of inflammatory cascade,  in presence or absence of infection, 
leading to initiation of labouring mechanisms within the myometrium. 
In this study, we hypothesized that Toll-like receptors (TLR 2 & 4) are expressed in labouring 
myometrium, and are involved in physiologic and pathophysiologic mechanisms of 
parturition. In order to test this hypothesis, we compared the pattern of expression of Toll-like 
receptors in myometrial samples obtained from consenting women before and after onset of 
term and preterm labour. We also aimed to investigate the activation, regulation of and the 
functional significance of TLR expression with respect to cytokine production in human 
myometrium at term, and to determine if progestogens could antagonise the effect of TLR 
ligands such as Lipopolysaccharide (LPS). 
We identified the synthesis and presence of TLR2 & 4 in human myometrium as shown by 
expression of their mRNA and protein signals which appear to be increasing by gestation and   11 
possibly by labour status. We also demonstrated a possible role for TLR2 as indicated by 
upregulation of its protein expression in labour compared with non-labouring myometrium. 
Although there was also  a trend to an increase in TLR4 with labour, this did not reach 
statistical significance. 
In our short-term tissue culture model, we demonstrated that Medroxyprogesterone acetate 
(MPA) significantly suppressed baseline and LPS induced production of IL-1β, IL-6 and IL-8 
in pregnant human myometrium. Although LPS stimulated IL-10 production, there was no 
significant inhibitory effect with MPA. In contrast, we failed to demonstrate significant 
upregulation of either TNF-α or IFN-γ in response to LPS, and there was no effect of MPA. 
We also showed that the specific inhibitor for double stranded-RNA dependent protein kinase 
(PKR) 2-Aminopurine significantly inhibited both baseline and LPS stimulated myometrial 
cytokine production. 
In conclusion, findings of this work have demonstrated a potential role for Toll-like receptors 
2 & 4 in initiation of term and preterm labour and an anti-inflammatory role for the 
progestogen Medroxyprogestrone acetate in lipopolysaccahride stimulated myometrial tissue 
culture model in vitro. These findings highlight the need for further studies to examine the 
role of other progestogens / progesterone, benefits and risks to mothers and to their babies, in 
prevention of preterm labour. 
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1.1  Premature labour 
Spontaneous preterm labour and preterm birth are the leading cause of perinatal morbidity 
and mortality worldwide. Preterm birth, spontaneous and medically induced,  complicated 
about 11.9% of all pregnancies in 2001 and the number of babies born preterm has been 
steadily increasing for the past two decades (1). Despite much effort during the past 40 years, 
nearly all of the improvements with treating this pregnancy complication have been due to 
advances in neonatology (2). Indeed, the probability of infant survival for 30 completed 
weeks of gestation is over 90 % and the limit of fetal survival has been extended to 24 weeks 
(3).  
The 2% of babies born before 32 weeks, however, account for about 70 % of all infant 
mortality. A preterm born infant incurs a 40-fold increase in neonatal mortality. Long term 
neurological and developmental deficits such as cerebral palsy, chronic respiratory illness, 
blindness and deafness have been identified in as many as 70% of children with birth weights 
below 800 grams (4). These complications are inevitably associated with substantial 
healthcare costs (5) consuming approximately 10% of all paediatric health care costs in the 
United States, for example, in additional expenditures on health, education, and childcare (6). 
Despite decades of investigation, the pathophysiology of premature labour is incompletely 
understood and consequently, therapies or preventive strategies tailored to each of the many 
potential causes do not exist. Spontaneous preterm labour appears to be a  final common 
pathway for multiple aetiologies involving the cervix, fetus, fetal membranes, placenta and 
finally manifests in the responding organ; the myometrium (7). Known causes of preterm 
labour include poor nutrition, alcoholism, smoking, infection, prelabour rupture of 
membranes, multiple gestation and coagulation disorders (3). A common theme of many of 
these conditions is inflammation at the maternal-fetal interface, mediated by pro-  14 
inflammatory cytokines (8). In turn, these will trigger a cascade of reactions ending the phase 
of myometrial quiescence and starting the process of labour. 
1.2  Parturition as an inflammatory process 
Parturition is the process of cervical ripening (softening) followed by contractions of the 
myometrium that leads into effacement and dilatation of the cervix and, finally, expulsion of 
the fetus. This process involves three independent processes: 
•  Remodelling of the cervix to allow it to dilate to the width of the reproductive tract 
•  Weakening and rupture of the membranes in the region overlying the cervix 
•  Finally, initiation of rhythmic uterine contractions 
Increasing evidence indicates that inflammatory mediators play a crucial role in parturition (9, 
10,  89). Young and colleagues (11) were among a group of investigators who showed a 
massive infiltration of leucocytes into the myometrium, cervix, fetal membranes and placenta 
during labour resulting in increased production of pro-inflammatory cytokines (e.g. IL-1β, IL-
6, IL-8 and TNFα) (12). IL-1 and TNFα have been isolated from amniotic fluid prior to the 
onset of uterine contractions (13). Moreover, IL-1 can induce preterm labour in animal 
models (14). 
Pro-inflammatory cytokines can induce ripening of the cervix in a number of ways. IL-1 β 
and TNFα increase the production of proteinases (matrix metalloproteinase MMP-1, MMP-3, 
MMP-9 and cathepsin S) that can digest the collagen and elastin fibres in the extracellular 
matrix of the cervix (15, 16). A similar effect occurring in the membranes can then weaken 
their tensile strength and lower their threshold for rupture (17). IL-1α and IL-1β have been 
shown experimentally to increase COX-2 and PGE2 production by rabbit cervical fibroblast 
cells  (18). Beside the ability of PGE-2 to increase the production of proteinases, it also   15 
increases the permeability of blood vessels for leukocytes trafficking. This effect is also 
shared by Nitric Oxide (NO), another inflammatory mediator that is increased at term (19). 
Release of cytokines during inflammatory process results in upregulation of various inducible 
enzymes such as cyclo-oxygenase2 (COX2) and inducible nitric oxide synthase (iNOS). 
Cyclo-oxygenase converts free arachidonic acid into prostaglandin precursors and one of the 
isoforms, Cyclo-oxygease2, is rapidly inducible and can increase during labour  (20). 
Prostaglandins have an important role in parturition and can stimulate uterine contractions. 
Additionally, Nitric Oxide, released by inducible Nitric Oxide Synthase (iNOS) stimulates 
processes important for labour such as cervical ripening (16). Both the iNOS and COX2 
genes are activated by the transcription factor Nuclear Factor-κB (NF- κB). Upregulation of 
NF- κB activity is now known to be central to the process of human labour at term (21). 
1.3  Role of infection 
Infection is the most frequent cause of Preterm Pre-labour Rupture of Membranes (PPROM) 
and Preterm Labour (PTL) and is clearly identifiable in more than 30% of cases (22). The 
ability of systemic maternal infections to cause the onset of labour together with the frequent 
association of intra-uterine infection with pre-term labour and delivery has led to the current 
acceptance of intra-uterine infection as a major causal agent of pre-term birth. The route of 
intra-uterine colonization is most likely to be through ascending infection and commonly 
associated organisms include: Ureaplasma urealyticum, Mycoplasma hominis, Streptococcus 
agalactae and Escherichia coli. However, an obligate systemic component to the pathogenesis 
of bacterially induced labour is almost certain  as mere microbial colonisation of the 
chorioamniotic membranes may not always elicit a fetal or maternal inflammatory response 
(23). In their interesting experiment on a murine model, Hirsch and Wang found that bacterial 
inoculation of a ligated uterine horn caused preterm delivery from the free horn in an   16 
inoculation dose-dependent fashion. Further, the potency of these inocula to cause PTL and 
also of similar inocula administered in a distant organ (e.g. renal parenchyma) was in no way 
less than that injected into the intact bicornuate uterui (24). 
Infection may cause preterm pre-labour rupture of membranes (PPROM) and preterm labour 
(PTL) by causing premature activation of cytokine cascades leading into activation of 
parturition mechanisms. A number of studies suggested that production of pro-inflammatory 
mediators such as IL-1 β, TNFα, IL-6, IL-8 and MMP-9 is increased during intra-amniotic 
infection, PPROM and PTL (14, 25, 26).  
As previously discussed, pre-term labour was experimentally induced in rodents or primates 
through administration of bacteria or bacterial products in late pregnancy. This was preceded 
by increased production of pro-inflammatory cytokines including TNFα and IL-1 β. In fact, a 
causal role for IL-1 β was suggested, as its administration was able to mimic the effects of 
bacterial administration by causing PTL (26). The source of these cytokines is unclear but 
may originate from trophoblast cells as well as fetal or maternal macrophages. Cytokines 
could be experimentally produced in cultures of amnion, chorion and decidual cells in 
response to bacteria or bacterial products. 
1.4  Human immune response 
Vertebrate immunity can be broadly categorized into:   
1.4.1  Adaptive immunity  
Adaptive immune responses are mediated by clonally distributed B and T lymphocytes and 
are characterized by specificity and memory. Recognition relies on the generation of a 
random and highly diverse repertoire of antigen receptors, the T-  and B-cell receptors, 
followed by clonal selection and expansion of receptors with relevant specificities (27). This   17 
mechanism accounts for the generation of immunological memory, an important advantage, 
but has the main limitation that specific clones need to expand and differentiate into effector 
cells before they can participate in host defense. Therefore, adaptive immune responses are 
typically delayed for 4 to 7 days. 
1.4.2  Innate immunity 
To control the infection during the first days, our body relies on the evolutionarily ancient and 
more universal innate immune system. Its main functions include opsonization, activation of 
complement and coagulation cascades, phagocytosis, activation of pro-inflammatory 
signalling cascades, and apoptosis (28). In contrast to adaptive immunity, it is non-specific, 
rapid and requires no previous exposure to antigens (immunologic memory).  
The innate immune system also has an important function in activation and shaping of the 
adaptive immune response through the induction of co-stimulatory molecules and cytokines 
(29). In contrast to the clonotypic receptors, expressed by B and T lymphocytes, the innate 
immune  system uses non-clonal sets of recognition molecules, called pattern recognition 
receptors. Pattern recognition receptors bind conserved molecular structures found in large 
groups of pathogens, termed pathogen-associated molecular patterns. There are various 
groups of pattern recognition receptors, which can be secreted, expressed on the cell surface, 
or resident in intracellular compartments (30). 
Based on their sub-cellular localisation, PRRs can be classified into: 
a)  Soluble PRRs: as acute phase proteins, mannan-binding lectin and CRP 
b)  Trans-membrane PRRs: as scavenger receptors, Toll-like receptors (TLRs) 1, 2, 4, 5 
and 11 
c)  Intracellular PRRs: as NOD1, NOD2, RIG-I family RNA helicases and TLRs 3, 7, 8 
and 9 (28)   18 
It seems that the innate rather than adaptive immunity plays the significant role in PTL. 
Although a previous preterm birth is the strongest predictor of a subsequent preterm birth, 
gestation length does not decrease in proportion to number of previous deliveries, as it would 
with a classical graft rejection mediated through the memory bearing adaptive (acquired) 
immunity. Conversely, many women are still able to have normal term pregnancies after a 
previous per-term birth (31, 32).  
Based on existing literature, an inflammatory process is started by presence of either bacterial 
products or other endogenous stimulus (9,  12,  33). This leads to activation of the innate 
immune system through cell surface recognition molecules such as the Toll-like receptors 
family. In turn, they produce an intracellular signal transduction process that results in release 
of cytokines, chemokines, proteases and other factors. These are the substances responsible 
for cervical ripening and conversion of the normally quiet uterus into a contractile organ. 
1.5  Toll-like receptors 
The Toll-like receptors (TLRs) are one of the most important pattern recognition receptor 
families that can discriminate between chemically diverse classes of microbial products. 
Furthermore, activation of innate
 immunity is a critical step to the development of antigen-
specific
 acquired immunity.  
At the end of the 20th century, Toll was shown to be an essential
 receptor for host defence 
against fungal infection in Drosophila,
 a fruit fly that has innate immunity only (35). One year 
later, a mammalian
 homologue of the Toll receptor with similar sequence (now termed TLR4) 
was shown to
  induce expression of genes involved in inflammatory responses  (36). In 
addition, a point mutation in the TLR4 gene has been
 identified in a mouse strain that is 
unresponsive to Lipopolysaccharide (LPS) (37).    19 
After the characterization of the first mammalian TLR, TLR4,
  several proteins that are 
structurally related to TLR4 were
 identified and named Toll-like receptors. Mammalian TLRs
 
comprise a large family consisting of at least 11 members. TLR1 – 9
 are conserved between 
the human and mouse. However, although
 TLR10 is presumably functional in the human, the 
C-terminal
 half of the mouse TLR10 gene is substituted to an unrelated
 and non-productive 
sequence, indicating that mouse TLR10 is
  non-functional. Similarly, mouse
  TLR11 is 
functional, but there is a stop codon in the human
 TLR11 gene, which results in a lack of 
production of human TLR11 (27, 38).
 Gene mapping studies have revealed that TLR genes 
are dispersed throughout the mammalian genome (30). 
      Table 1: Types of Toll-like receptors, their chromosomal location and related ligands 
Receptor type  Encoding gene 
location 
Microbial ligands 
TLR1  Chromosome 4  Triacyl lipopeptides 
TLR2  Chromosome 4  Lipoproteins, glcolipids and 
peptidoglycans of Gram-positive 
organisms 
TLR3  Chromosome 4  Double-stranded viral RNA 
TLR4  Chromosome 9  LPS of Gram-negative organisms 
TLR5  Chromosome 1  Bacterial flagellin 
TLR6  Chromosome 4  Diacyl lipopeptides 
TLR7  Chromosome X  Guanosine or uridine-rich single-
stranded viral RNA 
TLR8  Chromosome X  Guanosine or uridine-rich single-
stranded viral RNA   20 
TLR9  Chromosome 3  Unmethylatd bacterial CpG motifs 
TLR10  Chromosome 4  Possibly similar to TLR1 & TLR6 
TLR11  Chromosome 4  Non-functioning in humans 
             
(From Armant MA,) Fenton MJ, 2002) (30) 
 
1.5.1  Toll-like receptors and response to infection 
Toll-like receptors appear to mediate almost all the changes in gene expression induced by 
pathogens, including bacteria, viruses and fungi. Expression of TLR receptors is highest in 
peripheral blood leukocytes, macrophages and monocytes. They are a family of type I 
transmembrane receptors (as with TLRs 1, 2, 4, 5 and 11) or intracellular (as with TLRs 3, 7, 
8 and 9) (28). The transmembrane variety is characterized by an extracellular amino acid 
terminus. The cytoplasmic portion of TLRs shows high similarity to that
 of the IL-1 receptor 
family, and is termed a Toll/IL-1 receptor
  (TIR) domain. Despite this similarity, the 
extracellular portions
 of both types of receptors are structurally unrelated. The IL-1
 receptors 
possess an immunoglobulin-like domain, whereas TLRs
 bear leucine-rich repeats (LRRs) in 
the extracellular domain (39).
 How leucine-rich repeats mediate ligand recognition is still 
puzzling, especially as it was demonstrated that 7 out of 10 leucine-rich repeat motifs of the 
CD14 receptor, a transmembrane protein implicated in LPS recognition, could be deleted 
without affecting LPS binding. Furthermore, each TLR can recognize the most diverse 
ligands, lacking any structural similarity, making it hard to conceive how one motif can 
interact with all these molecules (40).   21 
1.5.2  TLRs ligands 
All products of microorganisms including bacteria, viruses, fungi and even parasites (e.g. 
LPS) might be considered to be the primary ligands the TLRs family. Typically, members of 
the TLRs family may contribute with each other for discrimination between different ligands 
and eliciting a distinct immune response accordingly (41).  
TLRs are also activated by other endogenous agents such as heat shock protein 60 and 70 and 
the extra domain A of fibronectin  (42,  43). Therefore, local activation of TLRs may be 
responsible for the initiation of inflammation within the myometrium during labour in the 
presence or absence of infection (44).  This mechanism has previously been shown in other 
inflammatory conditions such as distressed myocardium (45). Surfactant protein-A (SP-A) 
produced by alveolar type II cells has also been identified as a ligand for TLR4 however it 
can also act via TLR2.  SP-A treatment of human peripheral blood mononuclear cells, lung 
alveolar macrophages and monocyte cell lines caused rapid activation of NF-κB  and 
increased expression of proinflammatory cytokines (46).  Similarly, pulmonary surfactant 
isolated from human amniotic fluid stimulated prostaglandin synthesis in human amnion 
discs. Condon et al, (47) proposed that augmented production of SP-A by the maturing fetal 
lung either physiologically at term or pathologically preterm (in presence of infection) 
operates via TLRs to provides a key hormonal stimulus for the cascade of inflammatory 
signalling pathways within the maternal uterus that culminate in enhanced myometrial 
activity leading to parturition. Yuan et al, (48) studied the characterization of peripheral blood 
leukocytes and concluded that both term and preterm labour were associated with increased 
monocyte and neutrophil subpopulation and activation as indicated by increased neutrophil 
migratory ability and cell surface marker expression. Although this model has been shown to 
operate in mice, data from human studies suggest that migration of fetal macrophages from   22 
the amniotic cavity or the chorioamniotic membranes into myometrium does not occur during 
human labour which casts doubts on applicability of this model in human labour (49, 50). 
1.5.3  TLRs signalling pathways 
TLRs activate signal transduction pathways that induce expression of pro-inflammatory 
cytokines, chemokines and other immune response genes (Figure 1). Activation of specific 
TLRs leads to slightly different patterns of gene expression profiles. For example, activation 
of TLR3 and TLR4 signaling
 pathways results in induction of type I interferons (IFNs),
 but 
activation of TLR2- and TLR5-mediated pathways does not (51). TLR7, TLR8 and TLR9 
signaling pathways also lead
 to induction of type I IFNs through mechanisms distinct from
 
TLR3/4-mediated induction.  
Toll-like receptors, with the exception of TLR3, share a common signalling pathway via the 
adaptor molecule Myeloid Differentiation factor (MyD88) which has a segment of the 
cytoplasmic Toll/IL-1R (TIR) domain in its C-terminal region and a death domain (DD) in its 
N-terminal region. Upon stimulation, TLRs recruit MyD88 through interaction of their 
respective TIR domain. The DD of MyD88 then binds the DD of IL-1R associated kinase 
(IRAK) and the signal is propagated via TNF receptor associated factor-6 leading to 
activation of NF-κB and mitogen-activated protein kinases and transcription of relevant genes 
(38). Recently, a second TIR-containing adaptor protein, TIR-associated protein (TIRAP) / 
MyD88-adaptor like was identified to be involved in the MyD88-dependent pathways  of 
TLR1/2, TLR2/6 and TLR4 (52).  
In addition to the common MyD88-mediated signalling pathway, a MyD88-independent 
pathway has been identified that involves a third TIR-containing adaptor molecule, TIR 
domain-containing adaptor-inducing interferon-β (IFN-β; TRIF), which is essential for TLR3 
and TLR4 signalling, leading to induction of transcription factor IFN regulatory factor 3 and   23 
the subsequent production of IFN-β and activation and maturation of dendritic cells (53). 
Recently, a fourth TIR-containing adaptor molecule, TRIF-related adaptor molecule (TRAM) 
has been shown to be involved specifically in TLR4 mediated MyD88-independent IFN-β 
production. Thus, these adaptor molecules provide specificities for TLR-mediated signalling 
(54).
 
Figure 1: Schematic diagram of the trans-membrane group of mammalian Toll-like Receptors 
(TLRs) and their response upon stimulation by their potential ligands  
(PAMP: pathogen associated molecular pattern, EC: extracellular, IC: intracellular) 
(Sandor F & Buc M, 2005) (53)   24 
1.5.4  Control of TLRs expression 
Several reports suggest that Toll-like receptors expression is regulated in both a cell type and 
a stimulus-dependent fashion. According to their cellular expression pattern, TLRs can be 
categorised as either ubiquitous (as in TLR1) reflecting a possible role as a regulator of TLR 
signalling, restricted (as in TLR2, 4 and 5) or specific (as in TLR3) (41). Interestingly, TLRs 
expression declines with age (55) and also shows extreme variability among individuals; e.g., 
TLRs expression appears to be much higher in farmers’ children, which might correlate with 
individual differences in pathogen susceptibility (56). TLRs participate in positive feedback 
loops, since the very pro-inflammatory cytokines, whose expression TLR activation 
stimulates, also stimulates TLR expression. For example, IL-1β,  TNFα  and  IFNγ  induce 
TLR4 transcription in human monocytes and polymorphonuclear leucocytes (57), and TLR4 
activation consequently
 promotes further release of those cytokines. In human endothelial 
cells, TLR2 and TLR4 may be induced by LPS and IFNγ, leading to increased production of 
pro-inflammatory mediators (58). Since cytokines can themselves stimulate TLR expression, 
amplification loops promoting inflammatory responses through TLR likely exist. 
On the other hand, several molecules are postulated
 to modulate TLR signalling pathways. 
Exposure to microbial components such as LPS results in a severely
 reduced response to a 
subsequent challenge by LPS. This phenomenon was first described over 50 years ago (59) 
and in now called endotoxin (or LPS) tolerance, however mechanism remains unclear (60). In 
addition, molecules that negatively regulate TLR signalling
 have been identified. IRAK-M, a 
member of the IRAK family of
 serine/threonine kinases, is induced by TLR stimulation in 
monocyte/macrophages (61). Combination of
 these negative regulators may finely coordinate 
the TLR signaling
 pathway to limit exaggerated innate responses causing harmful
 disorders.
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1.5.5  Clinical implication 
Compelling evidence exists for the crucial role of TLRs in inflammation, therefore, targeted 
inhibition of TLR activation is an attractive therapeutic option in inflammatory conditions. 
Aldara (Imiquimod) was the first TLR drug to reach the market which was developed by 3M 
Pharmaceuticals (Minnesota) and was approved in 1997 as a cancer therapy before the TLR 
mechanism of action was well understood. Many drug candidates have since emerged of 
which two are currently in phase 3 clinical trials. The first, PF-3512676, is being developed 
by Coley Pharmaceuticals for non-small cell lung cancer, and the second is a hepatitis B 
vaccine being developed by Dynavax (Hipsilav) (62). Toshchakov VY et al, (2007) identified 
cell penetrating peptides which have the ability to selectively affect different TLRs signalling 
pathways (63). Cpn10 (heat-shock protein 10) has been used clinically in small trials for 
treatment of rheumatoid arthritis, psoriasis and multiple sclerosis (64). As we learn more 
about TLRs signal transduction, it is expected that more option would be available for 
pharmacological targeting of infectious diseases, cancer and allergies (65).  
1.6  Role of Progesterone in parturition 
A role for progesterone in maintaining pregnancy has been suggested since the early 1960s 
(66). Although the exact mechanism of onset of labour in human remains incompletely 
understood, it appears that progesterone does have a role in prolongation of pregnancy. In 
animal models, rodents show a rapid fall in peripheral progesterone concentration before term 
and preterm labour (67,  68).  However, administration of progesterone even in supra-
physiological doses did not prevent infection or inflammation-induced preterm birth in the 
same animal model (69,  70).  In early pregnancy, removal of the corpus luteum before 
establishment of placental progesterone production is associated with pregnancy loss (71). 
Pharmacological withdrawal of progesterone by administering 3-beta-hydroxysteroid   26 
dehydrogenase inhibitors is associated  with onset of labour and the anti-progesterone 
mifepristone has been used clinically in order to facilitate termination of pregnancy (72, 73). 
By contrast, women undergoing assisted reproductive techniques have been administered 
progesterone in order to maintain pregnancy (74).  Progesterone is believed to contribute 
towards maintenance of pregnancy by maintaining uterine quiescence which is postulated to 
occur through suppression of the calcium-calmodulin-myosin light chain kinase system, 
reducing the calcium flux and altering the resting potential of uterine smooth muscles (71). 
Nevertheless, it is important to note that preterm birth is not a homogenous disease and as 
such, it is expected that progestational agents may work best only for a select group of 
patients.  Vaginally administered progesterone did not prevent preterm birth in the double-
blind placebo-controlled STOPPIT study involving 500 women with twin pregnancy (109). 
While a fall in maternal progesterone concentrations has been noticed with connective tissue 
remodelling in the cervix in many animal species, these changes have not been documented to 
occur in women before labour. There are no apparent biochemical changes in circulating 
steroid hormones levels
  in human pregnancy  (75). However, a functional withdrawal of 
progesterone has been suggested whereby the myometrial relaxing effects of progesterone are 
nullified (76). Several mechanisms have been proposed including: sequestration of free active 
progesterone, local cellular inactivation of progesterone bioactivity, production of natural 
progesterone antagonists and changes in progesterone receptor subtypes expression. Two 
types of progesterone receptors have been described: the A-form and the B-form. The A-form 
appears to inhibit signal transduction of the B-form. Myometrial cells that were transfected 
with both receptors failed to initiate gene expression, whereas those transfected with the B-
form only did. The extent of progesterone responsiveness is inversely related to the 
progesterone-A/progesterone-B expression ratio. During labour, there is significant shift of 
progesterone receptor types in the myometrium from the B to the A-form causing a significant   27 
increase in the ratio, and there was significantly less expression of both receptors in the 
amnion (77, 78). In their observation on pregnant human myometrial cell culture, Madsen at 
al (2004) demonstrated a functional progesterone  withdrawal  effect to prostaglandins by 
increasing the myometrial progesterone A/B expression ratio mediated via the protein kinase-
A signalling pathway (79). 
In the cervix, a shift from B to the A-form of the receptors has also been described with no 
total change in progesterone receptors. Progesterone receptors have been found to be 
important to suppression of the inflammatory properties of estradiol in mice
.  It has been 
suggested that blockage of the function of progesterone receptors could permit pro-
inflammatory cascades to occur in utero at term in conjunction with rising estradiol levels.  
In order to assess the benefits and harms,  to mothers and to their infants, of its use in 
prevention of preterm birth, Dodd et al, (2008) identified eleven randomised controlled trials 
of progesterone supplementation for women at risk of preterm birth which met the inclusion 
criteria for their systematic review  (85). These studies involved 2425  women  and 3187 
infants.  Studies were subdivided by reason the women were considered to be at risk  for 
preterm birth. Trials were excluded if progesterone was administered for the treatment of 
actual or threatened preterm labour or if progesterone was administered for prevention of 
miscarriage. Their primary outcomes were perinatal mortality, preterm birth before 34 weeks 
of gestation, developmental delay in childhood. In their subgroup analysis, they also assessed 
the effect of time of treatment commencing before or after 20 weeks of gestation, route of 
administration and different dosage regimens divided into a cumulative dose of less than 500 
mg per week or a dose of equal to or greater than 500 mg per week. They showed that use of 
progesterone for women at risk of preterm birth is associated with a significant reduction in 
the  risk of preterm birth before 34  weeks’  gestation  (RR 0.15, 95% CI 0.04 –  0.64),   28 
significant reduction in the risk of infant birth weight less than 2500 g (RR 0.64, 95% CI 0.49 
–  0.83)  but no statistically significant differences for the outcome of perinatal death. 
Similarly, for women with a short cervix identified on ultrasound, progesterone was not 
associated with a significant reduction in perinatal death but there was a significant reduction 
in preterm birth before 34 weeks (RR 0.58, 95% CI 0.38 – 0.87) and a significant reduction in 
neonatal sepsis (RR 0.28, 95% CI 0.08 –  0.97).  For women with a  multiple pregnancy 
however, progesterone was not associated with any significant difference in perinatal birth or 
in preterm birth at less than 34 weeks of gestation. There was no differential effect on the 
outcomes when considering route of administration, time of commencement of 
supplementation or total weekly cummunlative dose of progesterone (80).  
Similarly, Sanchez Ramos, et al, in their meta-analysis of 10 randomized controlled trials that 
compared progestational agents with placebo for patients at risk for preterm birth, concluded 
that  the  use  of  progestational  agents  and  17  α-hydroxyprogesterone caproate reduced the 
incidence of preterm birth and low birth weight newborns (81).  
While promising, there remains a need for further large randomised controlled trials in order 
to assess more fully the benefits and potential risks, including those to the baby, and the 
optimal dose, route and timing of administration before its widespread supplementation for 
women considered to be at risk of preterm birth  (82). The same was highlighted in the 
committee opinion of the American College of Obstetricians and Gynecologists relating to the 
use of progesterone supplementation for women at the risk of preterm birth (83). The results 
of current randomized trials (84, 85) will assist in further elucidation of the precise role, 
benefits and harms of progesterone therapy for women and for their unborn babies considered 
to be at risk of preterm birth.   29 
1.7  Toll like receptors and mechanism of parturition 
This study explores the hypothesis that Toll-like receptors (TLRs) are expressed in labouring 
myometrium, and are involved in physiologic and pathophysiologic mechanisms of 
parturition. Since the putative TLR ligands, HSP70 and the extra domain A of fibronectin are 
known to be expressed in the myometruim, activation of the TLR by these endogenous 
ligands could activate invading inflammatory leukocytes, leading to cytokine release, 
autocrine enhancement of TLR expression and thus amplification of myometrial 
inflammation. Additionally, TLR mediated upregulation of COX2 could promote 
prostaglandin release, thus stimulating uterine contractions. Under pathological conditions of 
infection-associated pre-term labour, microbial-derived products e.g. LPS could activate TLR 
leading to aberrant initiation of labouring mechanisms within the myometrium. Thus, if our 
hypothesis of myometrial Toll-like Receptors expression and regulation is correct, they could 
be a novel target through which inappropriate pre-term parturition can be inhibited.    30 
 
1.8  Aims of this project 
•  To quantify TLR 2 & 4 mRNA and protein expression in human myometrial samples 
obtained from women before or after onset of spontaneous labour, both at term and 
preterm.    
•  To localise TLR 2 & 4 protein expression in human myometrium.  
•  To investigate the activation, regulation of and the functional significance of TLR 2 & 
4 expression with respect to cytokine production in human myometrium at term, and 
to determine if progestogens could antagonise the effect of TLR ligands such as 
Lipopolysaccharide (LPS).   31 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.  METHODS 
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2.1  Sample collection 
Myometrial tissue biopsies were obtained from the following groups of pregnant women: 
•  at term (≥ 37 weeks gestation) undergoing elective caesarean section prior to onset of 
labour 
•  at term undergoing emergency caesarean section during spontaneous labour 
•  preterm pregnancy (24 -36 weeks gestation) undergoing elective caesarean section 
before labour onset 
•  preterm pregnancy undergoing emergency caesarean section during spontaneous 
labour    
Women were excluded from the study if they had: 
•  a multiple pregnancy 
•  evidence of active infection: PROM for >24 hours, temperature >38o C 
•  induction of labour with prostaglandins or received oxytocic agents 
•  cervical dilatation < 4 cm or > 9 cm in labouring group   
Women were recruited from both the Princess Royal Maternity and from Ayrshire Central 
Hospitals. The study was approved by the Research Ethics Committee at North Glasgow 
Hospitals University NHS Trust (05/S0705/18) and from the LREC in Ayrshire and Arran 
NHS Trust (R&D 272), and was performed in accordance with the Declaration of Helsinki. 
Informed consent was obtained from each woman prior to recruitment.   33 
Myometrial biopsies were obtained from the upper margin of the lower uterine segment 
incision following delivery of the placenta and membranes as described by Thomson et al 
(10). All tissue specimens were divided in three parts: 2 parts were flash frozen in liquid 
nitrogen for total RNA and protein extraction and stored in 2 separate refrigerators at -70
o C 
in pre-cooled metal pots until processed. The third part was fixed intact in 10% buffered 
formalin (BDH, Poole, UK) for 24 hours then embedded in paraffin blocks, subsequently cut 
in 5μm thick sections for immunohistochemistry 
2.2  Real-time RT-PCR (TaqMan) 
2.2.1  RNA isolation 
The frozen tissue samples were ground using a mortar and pestle and the tissue transferred to 
a universal containing the appropriate amount of Trizol® (Invitrogen, 15596-018, Paisley, 
UK) [1 ml per 100mg of tissue]. Trizol® disrupts cells and dissolves the cell components 
freeing the RNA. The ground substance was homogenized in Trizol® using a homogenizer 
(Polytron®, Novara) for 45 seconds at speed of 5,000 rpm (1500g). The homogenate was 
aliquoted in 1 ml amounts into microcentrifuge tubes and incubated at room temperature for 5 
minutes to permit complete dissociation of nucleoprotein complexes. 0.2ml of chloroform 
was then added per 1 ml of Trizol® homogenate to allow separation of the solution into an 
aqueous phase and an organic phase. The tubes were shaken vigorously for 15 seconds until 
the solution turned a cloudy red colour. The samples were then incubated at room temperature 
(RT) for 3 minutes followed by centrifugation at 13,000 rpm (10,000g) for 15 minutes at 4
oC. 
The upper aqueous phase of the sample was transferred to a fresh tube. The RNA was then 
precipitated from the aqueous phase by mixing with isopropyl alcohol (0.5 ml of isopropyl 
alcohol per 1 ml of Trizol® used in the initial homogenization). The samples were then 
incubated at RT for 10 minutes then centrifuged at 13,000 rpm (10,000g) for 15 minutes at   34 
4
oC. Isopropyl alcohol was then poured off and 1 ml of 75% alcohol was added to each RNA 
pellet sample. At this stage, samples were stored at -70
oC until quantification. 
2.2.2  Quantification of RNA 
RNA samples were centrifuged at 10,000 rpm (6,000g) for 5 minutes at 4
oC, the ethanol was 
poured off and the tubes gently tapped constantly observing the pellets at the bottom of the 
tube. The tubes were inverted and placed on filter paper and the pellets dried at RT for 20 
minutes. An appropriate amount of Diethylpyrocarbonate- treated deionised water (DEPC 
DDW) was added to each pellet (to a large pellet, 40ul DEPC DDW and 15 ul to a small 
pellet). The samples were vortexed, spun down quickly and incubated at 65
oC for 5 minutes 
in a Dri-Block (Techne). Samples were once more vortexed, spun down and incubated for a 
further 5 minutes at 65
oC. All dissolved pellets from the same sample were combined in one 
tube and samples kept on ice at all times. The quantity of RNA present in the samples was 
calculated using a spectrophotometer (Ultrospec III, Amersham Pharmacia Biotech). 
Absorbance readings were taken at 260 nm and 280 nm. An aliquot of each sample was 
diluted in distilled water and placed in quartz cuvette. The spectrophotometer was first 
blanked with distilled water alone. The reading at 260 nm gives an indication of the amount 
of nucleic acid, in this case RNA, and the reading at 280 nm gives an estimation of the 
amount of protein present in each sample. The ratio of the 260 / 280 readings indicates the 
purity of the sample, for RNA a ratio between 1.8 – 2 being optimum. The 260 nm reading 
was used to calculate the amount of RNA present in each sample, 1OD unit at 260 nm is 
equivalent to 40 mg RNA. Samples were then DNase I treated to eliminate presence of 
genomic DNA contamination which can be amplified in the PCR process leading to a falsely 
high value for this sample.   35 
2.2.3  DNase treatment of RNA samples 
A DNA free kit (Ambion cat No.: 1906) was used to DNA decontaminate RNA samples. 
Briefly, to a 5 ul aliquot (upto5ug) of RNA, 16.5 ul of DEPC dH2O, 2.5ul of 10x DNase 
buffer and 1 ul of DNase I were gently mixed and incubated at 37
oC for 30 minutes in the 
OMN-E thermacycler. 2.5 ul of DNase inactivation reagent was then added and samples were 
incubated at room temperature for 2 minutes. Samples were centrifuged at 13,000 rpm 
(10,000g) for 1 minute to pellet the slurry DNase inactivation reagent and the supernatant 
solution containing the RNA was transferred to a fresh tube and stored at -70
oC. 
2.2.4  Converting RNA into cDNA 
RNA cannot serve as a template for PCR and hence a reverse transcription step is required to 
convert RNA into cDNA. High Capacity cDNA Archive Kit (Applied Biosystems, 
Warrington, UK, 4322171) was used for this purpose according to the manufacturers 
instructions . 2x Reverse Transcriptase (RT) TaqMan Universal PCR MasterMix was 
prepared for the required number of samples. 2x RT MasterMix was prepared from 10x RT 
Buffer, 25x dNTP, 10x random primers, multiscribe Reverse Transcriptase, RNase inhibitor 
and nuclease-free water. Each time, a negative control sample was included omitting the 
mutiscribe Reverse Transcriptase (no RT control) which can detect presence of genomic 
DNA contamination, if present. 16 ul of 2x MasterMix was added to 4 ul of DNase treated 
RNA samples and mixed by pipetting. Samples were then briefly centrifuged and incubated at 
25
oC for 10 minutes then 37
oC for 120 minutes (Omne programme 26). Serial dilutions from 
resulting cDNA (1/10 – 1/100,000) were prepared and samples were kept at -20
oC till used in 
TaqMan reaction.   36 
2.2.5  Real-time reverse-transcriptase PCR (RT-PCR) 
Real-time RT-PCR quantifies the initial amount of the template most sensitively and 
reproducibly and is a preferable alternative to other forms of quantitative RT-PCR that detect 
the amount of final amplified product at the end-point. Higuchi et al. (1993) pioneered the 
“real-time” analysis of PCR by constructing a system that detected PCR products as they 
accumulated  (86). The system is based on detection and quantification of a fluorescent 
reporter, which increases in direct proportion to the amount of PCR product in the reaction. 
By recording the amount of fluorescence emission at each cycle, it is possible the PCR 
reaction during exponential phase where the first significant increase in the amount of PCR 
product correlates to the initial amount of target template. The higher the starting copy 
number of nucleic acid target, the sooner a significant increase in florescence is observed. 
This method can be used for absolute or relative gene quantification and allelic discrimination 
assays that detects single base nucleotide mutations and polymorphisms. 
Real-time PCR does not detect the size of the amplicon and thus does not allow the 
differentiation between DNA and cDNA amplification. However, unlike other quantitative 
PCR methods, real-time PCR does not require post-amplification processing, preventing 
potential PCR product carry-over contamination, thereby substantially increasing throughput 
(87).   37 
 
 (From ABI Prism
® 7700 Sequence Detection System) 
Figure 2: Schematic representation of Reverse Transcriptase Polymerase reaction (RT-PCR) 
 
2.2.6  Setting up 96 well plate 
It is important to set aside all reagents and equipments solely for RNA extraction and 
analysis. Contamination with RNase caused by poor sample handling techniques would 
degrade the RNA sample. The inadvertent introduction of a contaminating DNA or amplicon 
would lead to an erroneous result due to amplification of the contaminant. Therefore handling 
of equipments and reagents should always be carried out while wearing gloves. Accurate 
pipetting is also critical in order to ensure reproducible results. 
All samples were carried out in duplicates. In addition to the control samples including “water 
only” and “no RT” controls, the housekeeping gene “18S” was used as an endogenous control 
to adjust for variations in the RNA quantity between samples. The housekeeping gene “18S” 
had already been previously established in our laboratory for myometrium after comparing it 
with GADP and β-actin. Results of a preliminary test-plate using cDNA standards in different   38 
dilutions showed that the 1/100 diluted cDNA and the 18S (1/1000) produced a linear 
regression line and a Threshold Cycle (Ct values: defined as the fractional cycle number at 
which the fluorescence passes a fixed threshold) between 28  –  30. Therefore these 
concentrations were used in the rest of the 96 well plates. Sterile filter pipette tips were used 
at all times. 
We used fluorogenic-labelled TLR2 (Hs00152932_m1) & TLR4 (Hs00152939_m1) and 18S 
probes (4310893E) from Applied Biosystems. The PCR reaction mixture (Applied 
Biosystems) was prepared as follows: 2x TaqMan mastermix (12.5 ul), 20x target assay mix 
(1.25 ul), RNase free water (10.25 ul) and 1 ul of cDNA (1/100 dilution) were prepared 
giving a final reaction mixture of 25 ul per well. PCR reaction mixture was added to every 
well followed by cDNA, using a fresh tip for every sample. All experiments were carried out 
in duplicate. The plate was then spun at 1400 rpm (120g) before being placed in the 7900HT 
TaqMan Machine (ABI), in order to reduce the risk of air bubbles interfering with the laser 
beam. Thermal cycle conditions are as follows: 50
oC for 2 minutes, 95
o C for 10 minutes 
(activation of the AmpliTaq-Gold Polymerase) then 40 cycles of 90
o  C for 15 seconds 
(denaturation) followed by 60
o C for 60 seconds (annealing and extension). Fluorescence 
emission spectra are continuously monitored in real-time and analyzed by the 7900HT system 
using the SDS software. Once PCR run is complete, data collected during thermal cycling is 
saved and analysed using the Sequence detection software, which calculated the threshold 
cycle (CT) values. The expression of the target assays were normalized by subtracting the CT 
value of the 18S control from the CT value of the relevant target assay. The fold increase 
relative to the control was obtained by using the formula 2
-ΔCT   39 
2.3  Immunohistochemistry 
Immunohistochemistry staining is the application of immunological methods to cells or tissue 
sections to enable protein visualization by demonstration of a marker conjugated to the final 
reactant (secondary antibody). Immunohistochemistry was used for studying pattern of 
expression and localization of TLR2 & 4 protein in sections from paraffin embedded 
myometrial tissue. Principally, sections were deparaffinized first and rehydrated before 
applying the primary antibody. Enzyme-conjugated secondary antibodies were then applied 
and the specific staining was then visualized after adding the enzyme specific substrate. 
2.3.1  Preparation of Paraffin sections 
Tissue samples were fixed in 10% buffered formalin (BDH, Poole, UK) for 24 hours, 50% 
ethanol for 8 hours then 70% ethanol for up to 34 hours. The tissue was then cut and placed in 
uni-cassettes. Each cassette was then placed in a histokinette 2000 and was taken through the 
following solutions: methylated spirits for 1 hour, methylated spirit phenol for 1 hour 30 
minutes, industrial alcohol for 1 hour 30 minutes, then for 2 hours, 2 hours and 2 hours and 20 
minutes, industrial alcohol / chloroform (50/50) for 1 hour, chloroform for 1hour 30 minutes, 
2 hours, 2 hours and 2 wax treatments for 2 hours and 3 hours 30 minutes. The uni-cassettes 
were then transferred to metal uni-cassettes and embedded using a Tissue Tek 3. Sections 5 
μm thick were cut from the paraffin embedded tissue using a microtome (Leica RM 2135) 
mounted on 2% silane (Sigma) in acetone (BDH, Poole, UK) coated slides, heated to 60
oC 
overnight and stored in slide boxes until used. 
2.3.2  Dewaxing and antigen retrieval 
Paraffin sections were heated to 60
oC for 35 minutes, deparaffinized in in Xylene (2x 10 
minutes each), and rehydrated in 100% ethanol (2x 5 minutes each), 95% ethanol (2x 
5minutes each), 70% ethanol (1x for minutes), 50% ethanol (1x for 5 minutes) then Phosphate   40 
Buffered Saline (PBS, 1x for 5 minutes). Endogenous peroxidase activity was removed using 
0.5% of freshly prepared hydrogen peroxide in methanol for 30 minutes at room temperature 
then washed in PBS. Antigen retrieval was performed by microwaving in a pressure cooker at 
full power for 5 minutes in citrate buffer (10mM, pH 6.0). Slides were then left to cool and 
washed in H2O for 5 minutes.  
2.3.3  ABC method 
Sections were then blocked with 20% goat serum / 20% human serum for 30 minutes at room 
temperature in a humidified box. Excess blocking serum was then tapped off and sections 
were incubated overnight at 4
oC with the primary antibody (TLR2: 1/5,000 in 2% rabbit 
serum, TLR4: 1/1000 in 2% normal goat serum) in a humidified box. Sections were washed 
with PBS (2x for 5 minutes each) and the secondary antibody was added (TLR2: biotinylated 
anti-goat IgG diluted in 2% rabbit serum with 5% of normal human serum, TLR4: 
biotinylated anti-rabbit IgG 1/200 in 2% normal goat serum and 5% of normal human serum) 
and slides were incubated at room temperature for 30 minutes in a humidifies box. Sections 
were washed in PBS 2x for 5 minutes each then incubated with avidin DH / biotinylated 
horseradish peroxidase H reagent (Vector) in PBS for 30 minutes before washing in PBS 2x 5 
minutes each. The antigen was localized using 1 mg/ml Diaminobenzidine 
Tetrahydrochloride (DAB, Sigma, UK) 0.2% of hydrogen peroxide in 50mM Tris. Hcl, pH 
7.6 for 10 minutes at room temperature. Sections were washed in PBS for 5 minutes and in 
running tap water for a further 5 minutes, staining in Harris haematoxylin (Sigma) for 15 – 20 
seconds and finally washed in water. Sections were dehydrated through alcohol in a reverse 
way to the steps described in re-hydration step and mounted in DPX.  
Negative controls included slides incubated without the primary antibody and sections from 
tonsillar tissue were used as positive control for the primary antibodies.   41 
2.3.4  Image analysis 
An Olympus BX50 microscope with x4, x10, x20, x44 lenses, connected to a 3-CCD colour 
camera (JVC) was used for digital image capture using the image analysis programme Image-
Pro Plus 4. Images were imported to Adobe Photoshop 5.5 using the TWAIN 32 interface 
programme. Pictures were labelled and manually aligned using Adobe Photoshop software. 
2.4  Western blotting 
To determine protein expression of TLR2 & TLR4, western blot analyses were performed 
with tissue homogenates isolated using Trizol
®.
  
2.4.1  Protein quantification (Bradford assay) 
Protein content of each sample was estimated using the Bradford assay. The unknown protein 
is diluted to 1:100 in deionised distilled water. Protein standard containing a range of 0 – 10 
ug / mL by diluting standard protein (Sigma P 0914) in DDW is prepared. Bradford reagent is 
then added (1 mL) to each tube in duplicate, mixed and incubated for 5 minutes. Absorbance 
reading at 595 nm is measured twice with the spectrophotometer with the deuterium lamp off 
and the mean of 2 readings is calculated. A standard curve of absorbance versus micrograms 
of protein is prepared and amount of protein is determined from the curve equation chart. 
2.4.2  Western blotting 
The XCell SureLock MiniCell and XCell blot module kit (Invitorgen) (Fig. 3) were used for 
protein electrophoresis and blotting.  NuPage 4-12% Bis-Tris preset gel (NP0321, Invitrogen) 
was gently washed with running buffer solution to ensure that air bubbles are displaced from 
all wells. The gel is then placed in XCell SureLock tank and the upper buffer chamber is 
filled with 200 mL of running buffer solution (NP0002) containing 100 uL of the reducing 
agent DiThioThreitol (DTT) completely covering all the wells. Multimark Standard (LC5725,   42 
Invitorgen) is then loaded in the first well (8 uL), positive control in the second well [TLR2: 
SW480 Cell Lysate (SC-2219), TLR4: HL-60 Whole Cell Lysate (SC-2209) (Santa Cruz)] 
and the rest of the lanes are then loaded with 5 ug of the protein samples and the lower 
chamber is the filled with 600 mL of running buffer. The unit is then covered and electrical 
leads are connected at 100 V for 1 hour. 
 
Figure 3: Xcell SureLock MiniCell (Invitrogen) 
Gel is then transferred nitrocellulose membrane (LC 2000, Invitrogen) pre-soaked in transfer 
buffer solution containing antioxidant. Briefly, gel is placed on transfer membrane ensuring 
that any air bubbles in between are removed and placed between pre-soaked filter papers and 
2 pre-soaked blotting pads. The gel / membrane assembly is then fitted into the cassette with 
the gel closest to the cathode core (-) and returned to the tank. The inner buffer chamber is 
filled with the transfer buffer solution till the gel / membrane assembly is completely covered 
while the outer chamber is filled with deionised water and the lid is paced on the unit and 
electrical leads connected. Transfer is run at 30 V constant for 1 ½ hour with current between 
150 – 110 mA.    43 
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Figure 4: Schematic diagram illustrating principle of western blotting analysis 
 
The membrane is then transferred to a Tupperware box with filtered Marvel solution (5%) in 
Phosphate Buffer Solution (PBS) with pH of 7.3 and kept on a platform shaker for agitation 
of membrane during incubation at 4
o C overnight. The membrane is washed 3 times with PBS 
and Tween 20 (0.1%) with each wash lasting 2 minutes followed by the primary antibody 
(TLR2 Santa Cruz SC-8689, TLR4 Santa Cruz SC-1074) at a concentration of 1:100  in 
filtered Marvel solution with PBS (pH 7.3) for 2 hours at room temperature. Such antibodies 
had been previously optimised using different concentrations and durations of exposure to the 
primary and secondary antibodies. Membrane is then washed 3 times as before with PBS and 
Tween 20 (0.1%) each lasting for 2 minutes followed by the secondary blocking antibody (for 
TLR2: rabbit anti-goat HRP, Santa Cruz SC-2922, for TLR4: goat anti-rabbit horseradish 
peroxidase (HRP), Santa Cruz SC-2054) at a concentration of 1:10.000 for 1 hour at room 
temperature. Membrane is washed as above and finally, the chemiluminescent substrate 
(SperSignal
® West Pico, Pierce Biotechnology) is added as per manufacturer instructions for 
5 minutes. Blot is covered with clear plastic wrap and exposed to X-ray film (Fujifilm, UK) 
for 1, 2, 5 and 15 minutes. Membranes were eventually re-probed with β-Actin (Santa Cruz   44 
SC-1616) at a concentration of 1:500 overnight at 4
o C followed by secondary antibody anti-
goat HRP at a concentration of 1:2000 for 1 hour at room temperature followed by washing 
and chemiluminescent substrate as above. 
The density of expression bands on X-ray films were measured using Bio-Rad Multi-Analyst 
model GS-700 Image Densitometer. After adjustment of the contrast and background, 
different densities of the bands were measured in duplicates and averaged. 
2.4.3  Stripping of western blot 
Following immunoblotting, the blot could be reused by stripping and re-probing with anti-
TLR4 antibody. Basically, the blot was incubated with the stripping buffer at 50
oC for 30 
minutes with occasional shaking and was then washed 3 times (10 minutes each) with PBS 
and Tween 20 (0.1%). The blot was then re-blocked with Marvel 5% as above overnight 
before rewashing and probing with primary antibody. 
2.5  Myometrial short-term tissue culture 
This section of the study was performed to investigate the activation, regulation of and the 
functional significance of TLR expression with respect to cytokine production in human 
myometrium at term, and to determine if progestogens could antagonise the effect of TLR 
ligands such as Lipopolysaccharide (LPS). In preparation for this experiment, we have shown 
that LPS stimulates myometrial production of IL-6 in a dose dependent manner as measured 
by Enzyme-Linked ImmunoSorbent Assay (ELISA) 
2.5.1  Enzyme-linked immunosorbent assay 
This preparatory experiment was performed in order to select the LPS dose and time points 
for measuring myometrial cytokines in vitro. IL6 was used as an index cytokine for the 
inflammatory response.     45 
2.5.1.1  Setting up 24 wells plate 
Myometrial samples were obtained as described by Sehringer et al (88), transferred from 
maternity theatre to the laboratory in Hank’s Buffered Salt Solution (HBSS). In tissue culture 
hood, sample was washed 3 times in Dulbecco’s PBS to remove any excess blood. Weighed 
samples (100 mg)  cut into 3 pieces were put in a 24 well plate containing 1 mL of Iscove’s 
medium (Invitrogen) supplemented with Penicillin 100 U/mL, Streptomycin 100 ug /mL and 
Fungizone (Amphotricin) 250 ng/mL and pre-incubated at 37
o  C for 60 minutes in a 
humidified chamber. Samples were then transferred to a new 24 well plate containing fresh 
culture medium with P.gingivalis lipopolysaccharide & ultra pure S.minnesota 
lipopolysaccharide (InvivoGen, CA, USA) at concentrations of 10, 100 and 1000 ng/mL. 
Control well was run without addition of LPS and all samples were carried out in duplicate. 
The plate is kept in a humidified chamber at 37
o C. Two Aliquots 100 uL each were obtained 
from each well and stored immediately at -20
o C for ELISA testing at a later date. 
2.5.1.2  IL-6 immunoassay (ELISA)  
This assay employs the quantitative sandwich enzyme immunoassay. A flat-bottomed 96-well 
microplate with monoclonal antibody specific for IL-6 was used (Quantikine
®, R&D systems 
D6050).   46 
 
 
Basically, 100uL of the assay diluent RD1W was added to each well followed by 100 uL of 
Standard, sample or control. The plate is then covered with adhesive strip and incubated for 2 
hours at room temperature. This is followed by aspiration and washing of all well for a total 
of four times with the wash buffer and the plate is decanted by tapping and inverted against a 
clean paper towel. IL-6 conjugate is then added to each well and the plate is covered and 
incubated for two hours at room temperature and washed and decanted as before. Finally, 200 
uL of Substrate Solution is added to each well and the plate is protected from light and 
incubated for 20 minutes at room temperature followed by addition of the Stop Solution (50 
uL) to each well and the optical density of each well is determined within 30 minutes using a 
microplate reader set to 450 nm 
2.5.1.3  Lactate Dehydrogenase activity assay 
The Lactate Dehydrogenase (LDH) activity assay was performed in tissue culture medium 
obtained from all 24-wells plates in order to assess membrane integrity as an indicator of 
cytotoxicity by measuring the amount of cytoplasmic LDH released into the culture medium. 
The LDH assay is based on the reduction of NAD by the action of LDH. The resulting 
IL-6 monoclonal 
Antibody 
Biotinylated  secondary
 
Antigen 
IL-6 
Figure 5: Schematic diagram illustrating the principles of enhanced-sensitivity ELISA using 
Biotin-Streptavidin system. IL-6 monoclonal antibody was used to coat the plate and capture 
the antigen. IL-6 was detected by a biotin-labeled secondary antibody which was in turn 
detected by an HRP-labeled streptavidin and the luminescent signal was detected by a plate 
reader. 
HRP Streptavidin   47 
reduced NAD (NADH) is utilized in the stoichiometric conversion of a tetrazolium dye and 
the resulting coloured compound is measured spectrophotometrically. The Lacate 
Dehydrogenase based in-vitro toxicology assay kit (TOX-7, Sigma-Aldrich, St Louis, USA) 
was used for this purpose. 
Cultures were removed from incubator into laminar flow hood and plates were centrifuged at 
2500  rpm  for 4 minutes  to separate supernatant from intact cells.  Aliquots were then 
transferred to clean flat-bottom plate  and Lactate Dehydrogenase assay mixture is then 
prepared by adding 25 ml of DEPC water to bottle of lyophilized enzyme and added in 
amounts equal to half of the volume of culture medium. The plate is covered by an opaque 
material (Aluminium foil or a box) to protect it from light and incubated at room temperature 
for 20 – 30 minutes. The reaction is then terminated by addition of 1/10 volume of 1N HCl 
solution to each well. Finally, absorbance was measured spectrophotometrically (LKB 
Biochrom Ultrospec II, UK) at a wavelength of 490 nm in a plate reader. The background 
absorbance of multiwell plates was measured at 690 nm and was subtracted from the primary 
wavelength measurement. 
 
2.5.2  Bio-Plex suspension array measurement 
The aim of these detailed experiments is to measure the human myometrial expression of 
cytokines IL-1β,  IL-6, IL-8, IL-10, TNF-α  and  IFN-γ  in  response  to  stimulation  by 
P.gingivalis lipopolysaccharide (InvivoGen, CA) as a ligand for TLR2 
2.5.2.1  Setting-up 24-well plate 
Weighed myometrial samples (n=8) obtained from women undergoing elective CS were 
washed 3 times in Dulbeccos PBS to remove any excess blood, then cut into small pieces   48 
using a sterile scalpel (100 mg weight) in tissue culture hood. Three small pieces of 
myometrium were put into each well of a 24 well plate containing 1ml of Iscoves medium 
supplemented with 100U/ml penicillin, 100ug/ml streptomycin  and 250ng/ml fungizone 
(amphotericin). After a pre-incubation at 37
oC for 45 minutes in humidified chamber the 
explants were transferred to a new well containing fresh culture medium. 
 The explants were incubated for 24 hours with no additional treatment (“control”), 100ng/ml 
purified P.gingivalis LPS - a known TLR2 ligand (“LPS”) InvivoGen, CA, USA), 2mg/ml 
Medroxyprogesterone acetate (“MPA”) (Pharmacia & Upjohn), LPS with MPA or finally 
LPS with the PKR inhibitor 2-Aminopurine 10mM. Control wells were run without addition 
of any of these chemicals. All samples were tested in duplicate.  
2.5.2.2  Cytokine assay 
Expression of cytokines IL-1β, IL-6, IL-8, IL-10, TNFα, and IFNγ were measured in the cell 
culture supernatant using the Bio-Plex suspension array system (Bio-Rad) which is a 
multiplex bead-based assay designed to quantify multiple cytokines in diverse matrices using 
the X-MAP technology 
Guided by IL-6 assay and performance characteristics of Bio-Plex assay, tissue culture 
supernatants used in this experiment as well as cytokine standards were 1/100 dilution. Bio-
Plex standard is reconstituted in 500 uL of Iscove’s medium (Invitrogen), gently vortexed and 
incubated for 30 minutes in ice. Bio-Plex beads working solution is then prepared, kept in ice 
in a foil wrap to protect it from light. 96-well filter plate is made wet with 100 uL of Bio-Plex 
assay buffer in each well followed by vacuum filtration to dry the filter plate. Bio-Plex beads 
working solution is then vortexed for 15 – 20 seconds at medium speed and added to wells, 
50 uL each followed by vacuum filtration. Filter plate is then washed with 100 uL of Bio-Plex 
wash buffer into each well and removed again by vacuum filtration. Diluted standard to   49 
samples are then added 50 uL into each well using a fresh pipette tip each time and the plate 
is covered with sealing tape and foil, shaken for 30 minutes at room temperature. Buffer 
solution is then removed by vacuum filtration and washed 3 times with wash buffer solution. 
Bio-Plex detection antibody solution is added 25 uL to each well, covered and shaken for 
further 30 minutes as before and buffer is removed by vacuum filtration. Plate is then washed 
3 times with wash buffer followed by vacuum filtration after each wash. Streptavidin-PE is 
finally prepared adding 50 uL to each well, plate is then covered shaken for 10 minutes at 
room temperature and washed 3 times followed by vacuum filtration. Before the plate is read 
in Bio-Plex system, the beads are re-suspended with 125 uL of Bio=Plex assay buffer solution 
into each well and the plate is covered with sealing tape and briefly shaken at 1100 rpm for 30 
seconds. 
Results are expressed as pg/ml/mg of tissue except for IL-6 & IL-8 which are expressed as 
ng/ml/mg of tissue. 
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2.6  Statistical analysis 
In order to study effect of a potential interaction between gestation and labour status on the 
dependent variables, a two-way between-group analysis of variance (ANOVA) was 
conducted. Two-way between-group analysis of variance is appropriate where there are two 
independent factors specifying the nature of the measurements (108). Where there was no 
significant interaction between gestation and labour, the main effect of these variables was 
reported as recommended.  Where there was a significant interaction, the effects of labour and 
gestation were analysed and reported separately using either a two-sided t-test if the data were 
normally distributed or a Mann-Whitney U test if not normally distributed. 
RT-PCR and Western blotting results were expressed as the Median ± IQR (data not normally 
distributed). To determine the differences between labouring and non-labouring samples, 
Mann-Whitney test was performed.  
Cytokine concentration was compared between all treatment wells using the Kruskal-Wallis 
test. If significant, differences were explored between control and each of LPS and MPA, LPS 
and LPS/MPA and between LPS and LPS/2AP using the Mann Whitney test (P < 0.05).  51 
 
 
 
 
 
 
 
3.  RESULTS   52 
3.1  Patients demographics 
  Term  Pre-term 
  In labour  Before labour  In labour  Before labour 
Number  23  37  5  12 
Mean age  27.7 ± 6.5  30.7 ± 5.9  32 ± 6.1  30.9 ± 4.8 
Gestation  39.6 ± 1.12  38.8 ± 0.6  34.4 ± 1.34  33.4 ± 1.5 
Indication  FTP: 12 
Brow: 1 
Fetal distress: 6 
Previous CS: 4 
Previous CS: 19 
Breech: 7 
IUGR: 1 
Maternal choice: 4 
Other: 6 
Previous 2 CS: 2 
Breech: 1 
Fetal distress: 2 
IUGR: 5 
Severe PIH: 5 
IDDM: 2 
Table 2: patients’ characteristics and indications of delivery 
CS:      Caesarean section 
IUGR:  Intrauterine growth restriction 
IDDM: Insulin dependent diabetes mellitus 
PIH:     Pregnancy-induced hypertension 
 
3.2  mRNA expression of TLR2 and TLR4 
In term myometrial samples, mean percentage values (± SEM) for TLR2 and TLR4 mRNA 
expression were [TLR2 105.53 (± 123.2) & TLR4 104.29 (± 118.6) (p = 0.06)], in labouring 
and [TLR2 30.9 (± 41.5) & TLR4 90.13 (± 140.8) (p = 0.88)], in non-labouring samples 
respectively.  However, mean percentage values of TLR2 and TLR4 expression were 
significantly higher in myometrium at term [TLR2 56.7 (± 12) & TLR4 95 (± 18.4), p=0.009] 
compared with preterm myometrium [TLR2 8.8 (± 4.01), TLR4 14.85 (± 5.81), p= 0.03] 
respectively. (N = Term before labour: 37, Term in labour: 23, Pre-term before labour: 12, 
Pre-term in labour: 5)   53 
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        Figure 6: Expression of TLR2 & 4 mRNA in relation to gestation and labour status 
        a > b (P = 0.009) 
        c > d (P = 0.03) 
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3.3 TLR2 and TLR4 protein expression 
On western blotting, a positive band corresponding to TLR2 protein was seen at 90kDA, to 
TLR4 at 89kDA and to β-actin at 43kDA. TLR2 protein expression was significantly 
increased in labouring myometrium (Mean = 23.3 ± 14.4,) as indicated by the density of the 
expression band on the blot in comparison with non-labouring myometrium at term (4.43 ± 
3.8, p=0.004). TLR4 protein expression was similar in labouring and in non-labouring 
myometrium (5.47 ± 11.6 versus 6 ± 15.1, p = 0.86). However, in contrast to our previous 
mRNA data, we could not demonstrate statistically significant differences in TLR2 & 4 
protein expression in term versus preterm myometrium (TLR2 = 14.99 ± 9.9 versus 12.03 ± 
7.1, p = 0.9, TLR4 = 9.44 ± 11.1 versus 7.13 ± 14.1, p = 0.62) (N = Term before labour: 9, 
Term in labour: 9, Pre-term before labour: 9, Pre-term in labour: 5) 
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Figure  7:  western blotting of TLR2 protein expression in relation to labour status and 
gestation. Lane 1 (M): MultiMark Standard (LC5725, Invitrogen), lane 2: positive control 
(SW cell lysate, SC2219), Lanes 3 –  6:  myometrium at term in labour, lanes 7 –  10 
myometrium at term before labour (Blot 1), Lanes 3 – 6 preterm myometrium in labour, 
Lanes 7 – 10: preterm myometrium not in labour (Blot 2)  
e > f (P = 0.004) 
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Figure  8:  western blotting of  TLR  4 protein expression  in relation to labour status and 
gestation. Lane 1 (M): MultiMark Standard (LC5725, Invitrogen), lane 2: positive control 
(HL60 whole cell lysate, SC2209), Lanes 3 – 6: myometrium at term in labour, lanes 7 – 10 
myometrium at term before labour (Blot 3), Lanes 3 – 6 preterm myometrium in labour, 
Lanes 7 – 10: preterm myometrium not in labour (Blot 4)       
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3.4  Immunohistochemical characterization of TLR2 & 4 expression 
As previously noted in our laboratory and also by other investigators, labour is associated 
with widespread infiltration of myometrium with leukocytes. Expression of both TLR2 and 
TLR4 was readily noticed around blood vessels and in infiltrating leukocytes in myometrial 
sections in labour. 
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Figure 9: Immunolocalization of TLR2 & 4. a: TLR2 at term before labour, b: TLR2 at term 
in labour, c: TLR4 at term before labour, d: TLR4 at term in labour, e: TLR2 preterm before 
labour, f: TLR2 preterm in labour. (magnification  x40).  TLR2&4 protein expression 
visualized as a brown stain using diaminobenzidine is more pronounced around blood vessels 
and in infilterating leukocytes as indicated by the arrows. 
c   
e  f 
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3.5  Cytokine release by LPS, MPA and 2AP treated short-term myometrial 
tissue in vitro 
In preparation for this experiment, we have shown that lipopolysaccharide (LPS) stimulates 
cytokine production in a dose and time dependent manner. (Figure 10) (N = 3) 
 
 
Figure 10: IL-6 production of human myometrium in response to stimulation by  
            P.gingivalis LPS (LPS2) and S.minnesota LPS (LPS4) 
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MPA significantly suppressed baseline (un-stimulated samples) and LPS induced production 
of IL-1β, IL-6 and IL-8 in pregnant human myometrium. Although P.gingivalis LPS (LPS 2) 
stimulated IL-10 production, there was no significant inhibitory effect with MPA. In contrast, 
we failed to demonstrate upregulation of either TNF-α or IFN-γ in response to LPS, and there 
was no effect of MPA (Table 3) 
2 Aminopurine which is a specific inhibitor for double stranded-RNA dependent protein 
kinase (PKR) significantly inhibited both baseline (un-stimulated) and LPS stimulated 
myometrial cytokine production. (Figure 11) 
  Control  LPS  MPA  LPS+MPA  P
*  2-AP  LPS+2AP  P
** 
                 
IL-1β  214 
(±53) 
549  
(±71) 
402.6 
(±26) 
462  
(±70) 
0.04  68.5 
(±16) 
120  
(±81) 
 
0.008 
IL-6  396.4 
(±52.9) 
771.3 
(±157.5) 
122.2 
(±9.5) 
222.7 
(±45.2) 
0.001  31.3 
(±9.7) 
6.4  
(±0.2) 
 
0.04 
IL-8  488.7 
(±105.9) 
982.7 
(±136.9) 
193.2 
(±46.5) 
399.6 
(±129) 
0.007  13.1 
(±6.2) 
3.8  
(±0.1) 
 
0.008 
IL-10  425 
(±102) 
1453 
(±333) 
625 
(±46) 
743  
(±255) 
0.08  110.5 
(±30) 
19.98 
(±5.7) 
 
0.03 
TNF-α  2420 
(±519) 
3482 
(±679) 
2523 
(±168) 
2436 
(±523) 
0.3  528 
(±201) 
67.1 
(±0.2) 
 
0.04 
IFN-γ  4207 
(±461) 
5522 
(±583) 
3367 
(±168) 
4639 
(±1319) 
0.2  611 
(±217) 
64.8  
(±55) 
0.03 
 
Table 3: cytokine production by LPS, MPA and 2-AP short term myometrial tissue culture 
P
*: compares cytokine expression by LPS stimulated samples with LPS + pre-treatment with 
Medroxyprogesterone acetate (MPA) 
P
**: compares cytokine expression by LPS stimulated samples with LPS + pre-treatment with 
2-Aminopurine (2-AP) (N = 6)   61 
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Figure 11: effect of P-gingivalis Lipopolysaccharide (LPS), Medroxyprogesterone acetate 
(MPA) and 2-Aminopurine (2-AP) on cytokine production by human myometrium at term 
(*)= p < 0.05, a: compares LPS + MPA pre-treated myometrial samples to LPS stimulated 
samples, b: compares LPS + 2AP to LPS. Control: un-stimulated samples. (N = 6) 
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4.  DISCUSSION   64 
Discussion 
In this study, we examined the hypothesis that Toll-like receptors are expressed in human 
myometrium and may play an important role in recognizing presence of the “danger signals” 
and initiation of the inflammatory cascade. 
We identified the synthesis and presence of TLR2 & 4 in human myometrium as shown by 
expression of their mRNA and protein signals. mRNA expression of myometrial TLRs, as 
measured by RT-PCR  showed significant upregulation at term compared with preterm 
gestation (TLR2 : p = 0.009, TLR4: p = 0.03).  
Moreover, labour status also appears to modify the pattern of expression of TLRs.  We 
demonstrated a possible role for TLR2 in labour as indicated by upregulation of its protein 
expression in labour compared with non-labouring myometrium (p = 0.004). Although there 
was a trend to an increase in TLR4 with labour, this did not reach statistical significance - 
observations similar to those noted by other investigators using the mouse model (88).  
We also demonstrated that TLR2 protein  expression was significantly increased in term 
labouring myometrium (p = 0.004) which lends further support to the previous notion of a 
possible role for TLR2 in human parturition. 
It is possible that other members of the TLRs family may have similar role to play in human 
myometrium in labour which highlights the need for further studies in this field.  
Although real-time RT-PCR technology has allowed quantification of mRNA targets with a 
degree of precision, biological validity of the quantitative data should be considered before 
concluding any results. There is no universal agreement yet on the inherent basic issues of 
this technique such as quality and quantity control of RNA, analysis and reporting of results 
and particularly, internal referencing. In this study, the internal reference (housekeeping) gene   65 
“18S” had already been previously established in our laboratory for myometrium after 
comparing it with GADP and β-actin. It is also important noting that the preterm myometrial 
samples obtained before labour were collected from pregnant women with some disorders 
which are known to be associated with a degree of inflammation at the feto-maternal interface 
(e.g. IUGR, PIH and IDDM). 
Accumulating evidence suggest that inflammation whether triggered by infection or by one or 
more of the endogenous stress signals, can start the unidirectional feed forward process of 
labour manifested by a progressive cascade of molecular events that lead to induction of a 
common pathway of parturition involving cervical effacement, rhythmic uterine contraction 
and finally expulsion of the fetus and placenta (7, 110). The inflammatory processes involved 
in human parturition appear to involve the complex co-ordination of various signalling 
pathways within the cervix and myometrium. Activation of such signalling pathways may 
result in up-regulation of transcription factors such as NFκB which in turn may contribute to 
cytokine, prostaglandin release, apoptosis and cell cycle regulation (89 - 91). 
Since Toll-like receptors play a crucial role in recognition of a wide range of micro-organisms 
in addition to a host of possible endogenous ligands, it could be anticipated that defective 
signalling through TLRs pathway can have an effect of initiation of inflammatory cascade 
leading into myometrial activation associated with term or preterm labour. This is also 
supported by the finding of a strain of mice with a spontaneous mutation for TLR4 that was 
resistant to deliver preterm after intrauterine inoculation of heat-killed bacteria or 
lipopolysaccahride administration compared with wild type mice (24). Moreover, 
spontaneous labour at term or preterm was found to be associated with increased mRNA and 
protein expression of TLR2 and TLR4 in the chorioamniotic membranes (92). Our finding of   66 
TLR2 and TLR4 expression in human myometrium would lend further evidence for the role 
of innate immune response in the mechanism of parturition. 
As previously discussed, Toll-like receptors, with the exception of TLR3, share a common 
signalling pathway via the adaptor molecule MyD88 which has a Toll/IL-1R (TIR) domain in 
its C-terminal region and a death domain (DD) in its N-terminal region. Upon stimulation, 
TLRs recruit MyD88 through interaction of their respective TIR domain. The DD of MyD88 
then binds the DD of IL-1R associated kinase (IRAK) and the signal is propagated via TNF 
receptor associated factor-6 leading to activation of NF-κB and mitogen-activated protein 
kinases and transcription of relevant genes (53,  93). Recently, a second TIR-containing 
adaptor protein, TIR-associated protein (TIRAP)/MyD88-adaptor like was identified to be 
involved in the MyD88-dependent pathways of TLR1/2, TLR2/6 and TLR4 (94).  
In addition to the common MyD88-mediated signalling pathway, a MyD88-independent 
pathway has been identified that involves a third TIR-containing adaptor molecule, TIR 
domain-containing adaptor-inducing interferon-β (IFN-β; TRIF), which is essential for TLR3 
and TLR4 signalling, leading to induction of transcription factor IFN regulatory factor 3 and 
the subsequent production of IFN-β and activation and maturation of dendritic cells (53). 
Recently, a fourth TIR-containing adaptor molecule, TRIF-related adaptor molecule (TRAM) 
has been shown to be involved specifically in TLR4 mediated MyD88-independent IFN-β 
production. Thus, these adaptor molecules provide specificities for TLR-mediated signalling. 
In our short-term tissue culture model, we demonstrated that Medroxyprogesterone acetate 
(MPA) significantly suppressed baseline (cytokines  produced in vivo proior to sample 
collection of in vitro during process of tissue culture) and LPS induced production of IL-1β, 
IL-6 and IL-8 in pregnant human myometrium. Although LPS stimulated IL-10 production, 
there was no significant inhibitory effect with MPA. In contrast, we failed to demonstrate   67 
significant upregulation of either TNF-α or IFN-γ in response to LPS, and there was no effect 
of MPA. The pattern of expression of IL-10 in our myometrial tissue culture model is not 
consistent with its previously noted role  in maintenance of pregnancy  due to its anti-
inflammatory effect. Previous studies have shown that IL-10 production is significantly 
reduced in the placenta at term without labour compared with that in first and second 
trimester tissue (95). Its expression was also noted to be reduced in the placental tissue of 
pregnancies complicated by preterm labour and chorioamnionitis when compared with 
placental tissues from normal controls. Administration  of IL-10  was also noted to block 
interleukin-1β  (IL-1β)  induced  uterine  contractions  in  pregnant  rhesus  monkeys  (96). 
Although IL-10 was also able to inhibit cyclooxygenase type 2 (COX-2) mRNA expression in 
cultured human placental explants from pregnancies complicated by preterm labour, it failed 
to do a similar effect in term labouring human myometrial explants (97). This may indicate 
that the mechanisms involved in regulation of inflammatory response during term labour may 
be different from preterm labour. 
We also showed that the specific inhibitor for double stranded-RNA dependent protein kinase 
(PKR) 2 Aminopurine significantly inhibited both baseline and LPS stimulated myometrial 
cytokine production in a dose dependent manner. This effect is believed to be achieved 
mainly via prevention of Toll/IL-1 receptor domain (TRIF)-dependent rather than myeloid 
differentiation factor (MyD)88-dependent signalling (98). This finding lends further support 
to the significant role of TLRs in initiating inflammatory response as manifested by cytokine 
production in human myometrium at term. 
Although animal studies have clearly demonstrated that interleukin-1 (IL-1) and tumour 
necrosis factor-α  (TNF-α) can induce labour (14,  26,  99), the question whether these 
cytokines do so during in vivo infections remains a difficult one to answer. Given the   68 
complexity and redundancy of inflammatory response networks, it is likely that no single 
mediator will be identified as responsible for the induction of labour during infection. Preterm 
labour can still occur in knockout mice for the IL-1 type I receptor after exposure to bacteria, 
suggesting that IL-1 administration is sufficient but not necessary for the onset of labour in 
the context of infection (100).  However, blockade of both IL-1 and TNF-α  signalling  in 
double knockout mice models has been associated with a decreased rate of preterm birth after 
bacterial inoculation. (101) 
It is possible that TLRs may co-operate with other inflammatory receptors for induction or 
amplification of inflammatory response. TREM-1 (Triggering receptor in myeloid cells-1) is 
a newly discovered receptor, which is intimately involved in inflammatory processes.  The 
specific ligands for TREM-1 remain unknown at present, but once activated TREM-1 acts as 
a critical amplifier of inflammatory signalling (100 - 102). TLR and TREM-1 may cooperate 
closely to induce an inflammatory response, as activation of TREM-1 causes a marked 
increment in the production of pro-inflammatory cytokines by macrophages when LPS is used 
as the co-stimulus. In contrast, TLRs directly recognise certain microbial products and 
components and using their adaptor molecules, they can potentially induce the production of 
proinflammatory cytokines via activation of NF-κB.  If  specific  ligands  for  TREM-1 are 
located at the foci of microbe-induced inflammation, interaction then between TREM-1 and 
TLRs can synergistically induce inflammatory responses (103 - 105). Unfortunately, due to 
time and financial constraints, it was not possible to study the patterns of expression of TLR2 
& TLR4 in the myometrial short term tissue culture samples to see if there is any correlation 
between cytokines production and TLRs profiles.  
Although the concept of an important role for progesterone in maintaining pregnancy and 
prevention of preterm labour was put forth in the 1950s (65), it has recently gained   69 
momentum with the findings of the Meis trial (2003) (81) and the recent support of the 
ACOG that 17P hydroxyprogesterone should be considered in high risk women to prevent 
preterm labour (82). The mechanisms by which progesterone administration prevent preterm 
birth remain speculative. Progesterone is known to promote myometrial quiescence, down 
regulate gap junction formation, inhibit cervical ripening and decrease the  production  of 
cytokines (e.g. IL-8) by chorioamniotic membranes (66,  67,  68,  70). Administration of 
progesterone receptor antagonist (i.e. Mifepristone or Onapristone) has been found to induce 
labour in pregnant women, non-human primates and in guinea pigs (71, 72). In many species, 
but not in humans, non-human primates and guinea pigs, a fall in maternal serum 
progesterone concentration occurs prior to spontaneous onset of parturition  (74,  75). 
However, the concept of “functional progesterone withdrawal” has been suggested by some 
investigators (76 - 78) which may be invoked by: 
-  reduced availability of progesterone by binding to a high affinity protein 
-  competitive inhibition from increased cortisol concentration in late pregnancy on their 
common glucocorticoid receptor 
-  increased peripheral conversion of progesterone to an inactive form 
-  changes in progesterone receptor isoforms 
-  suppression of NF-κB by activated progesterone receptors 
Our data from the short term myometrial tissue culture model lend further support to the 
hypothesis that progesterone may inhibit preterm labour via an anti-inflammatory effect. 
Further studies are needed to elucidate the specific roles and mechanisms of progesterone and 
progesterone-like agents in prevention of inflammation induced preterm birth and to identify 
the most effective preparation for this purpose.   70 
In conclusion, findings of this work have demonstrated a potential role for Toll-like receptors 
2 & 4 in initiation of term and preterm labour as manifested by their increased mRNA and 
protein expression with gestation and possibly with labour. We also demonstrated an anti-
inflammatory role for the progestogen Medroxyprogestrone acetate in lipopolysaccahride 
stimulated myometrial tissue culture model in vitro which highlights the need for further 
studies to examine the role of other progestogens / progesterone in prevention of preterm 
labour. The results of current, long awaited, randomized trials (83, 84) will assist in further 
elucidation of the precise role, benefits and harms of progesterone therapy for women 
considered to be at risk of preterm birth.   71 
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